MVision AI is a pioneering software service provider for precision radiotherapy treatment planning. The company, founded in 2017 and based in Finland, is focused on developing responsible AI tools to optimize efficiencies for radiotherapy departments and clinical teams. Their AI-powered segmentation tool aims to standardize and automate contouring, streamlining the radiotherapy treatment planning workflow. This innovative solution has been used to treat over 170,000 cancer patients in 16+ countries.
The latest milestone for MVision AI was the €5.40M Seed Round investment on 23 March 2023, with participation from Voima Ventures and J12. The deep learning models developed by MVision AI deliver consistent automated contouring in minutes, significantly reducing the hours of manual work traditionally required while upholding the highest standards of quality for every patient, every time. In summary, MVision AI is leveraging AI, biotechnology, and SaaS to revolutionize radiotherapy treatment planning with their innovative and impactful solutions.
No recent news or press coverage available for MVision AI.